top of page

White Papers

Ketoprofen

Ketoprofen

Gabapentin

Gabapentin

Naltrexone

Naltrexone

Focus: Addiction drug shows promise lifting long COVID brain fog, fatigue

Date: 10.18.2022

CHICAGO, Oct 18 (Reuters) - Lauren Nichols, a 34-year-old logistics expert for the U.S. Department of Transportation in Boston, has been suffering from impaired thinking and focus, fatigue, seizures, headache and pain since her COVID-19 infection in the spring of 2020. Last June, her doctor suggested low doses of naltrexone, a generic drug typically used to treat alcohol and opioid addiction. After more than two years of living in "a thick, foggy cloud," she said, "I can actually think clearly."   (Read more...)

Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study

Date: 10.24.2022

Up to 37.7% of patients experience symptoms beyond 12 weeks after infection with SARS-CoV-2. To date care for people with long covid has centred around multidisciplinary rehabilitation, self care and self pacing. LDN is safe in patients with PCS and may improve well-being and reduce symptomatology in this cohort. Randomised control trials are needed to further explore this.   (Read more...)

Low-Dose Naltrexone Could Treat Long COVID Symptoms

Date: 6.7.2023

Naltrexone is a drug approved by the Food and Drug Administration (FDA) to treat alcohol use disorder and opioid addiction. Low-dose naltrexone (LDN), usually at a fraction of the regular dose, has been used to treat fibromyalgia and multiple sclerosis.   (Read more...)

bottom of page